Loading company…
Prohealbiologix develops and sells biomolecule drugs for eye, immune and tumor diseases.
Founded in 2019 and based in Suzhou, China, Prohealbiologix researches, develops and produces biomolecule drugs for ophthalmic, immune and tumor diseases. Its pipeline includes PHP1003 injection and PHP0101 eye drops; PHP1003 has entered Phase II clinical trials. In June 2024, the company raised a CNY 40 million strategic investment to develop its ophthalmic pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in